BOTHELL, Wash.--(BUSINESS WIRE)--May 4, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN - News) today reported data from its ongoing phase II clinical trial of SGN-30 in cutaneous anaplastic large cell lymphoma (ALCL) and other lymphoproliferative disorders at the Society of Investigative Dermatology annual meeting being held in Philadelphia May 3-6. Multiple patients achieved objective antitumor responses to SGN-30 therapy, including both complete and partial responses. The study includes patients with relapsed or refractory CD30-expressing cutaneous T-cell disease, including cutaneous ALCL, transformed mycosis fungoides and lymphomatoid papulosis.
